Top

Journal of Cancer Survivorship

Published in:

01-06-2009

Skeletal sequelae of cancer and cancer treatment

Authors: Charles J. Stava, Camilo Jimenez, Mimi I. Hu, Rena Vassilopoulou-Sellin

Published in: Journal of Cancer Survivorship | Issue 2/2009

Abstract

Introduction

Survivors of cancer may experience lingering adverse skeletal effects such as osteoporosis and osteomalacia. Skeletal disorders are often associated with advancing age, but these effects can be exacerbated by exposure to cancer and its treatment. This review will explore the cancer and cancer treatment-related causes of skeletal disorders.

Methods

We performed a comprehensive search, using various Internet-based medical search engines such as PubMed, Medline Plus, Scopus, and Google Scholar, for published articles on the skeletal effects of cancer and cancer therapies.

Results

One-hundred-forty-two publications, including journal articles, books, and book chapters, met the inclusion criteria. They included case reports, literature reviews, systematic analyses, and cohort reports. Skeletal effects resulting from cancer and cancer therapies, including hypogonadism, androgen deprivation therapy, estrogen suppression, glucocorticoids/corticosteroids, methotrexate, megestrol acetate, platinum compounds, cyclophosphamide, doxorubicin, interferon-alpha, valproic acid, cyclosporine, vitamin A, NSAIDS, estramustine, ifosfamide, radiotherapy, and combined chemotherapeutic regimens, were identified and described. Skeletal effects of hyperparathyroidism, vitamin D deficiency, gastrectomy, hypophosphatemia, and hyperprolactinemia resulting from cancer therapies were also described.

Discussion/Conclusions

The publications researched during this review both highlight and emphasize the association between cancer therapies, including chemotherapy and radiotherapy, and skeletal dysfunction.

Implications for cancer survivors

These studies confirm that cancer survivors experience a more rapid acceleration of bone loss than their age-matched peers who were never diagnosed with cancer. Further studies are needed to better address the skeletal needs of cancer survivors.

NCI.SEER Cancer Statistics Review, 1975–2005. 2007; Available from: http://seer.cancer.gov/csr/1975_2005/.

Hewitt MGS, Stovall E. From cancer patient to cancer survivor, lost in transition. 1st ed. Washington, DC: National Academies; 2006.

Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003;104(4):488–95. doi:10.1002/ijc.10981.PubMed

Schultz PN, Klein MJ, Beck ML, Stava C, Sellin RV. Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors. J Clin Nurs. 2005;14(2):204–11. doi:10.1111/j.1365-2702.2004.01030.x.PubMed

Schultz PN, Stava C, Beck ML, Vassilopoulou-Sellin R. Ethnic/racial influences on the physiologic health of cancer survivors. Cancer. 2004;100(1):156–64. doi:10.1002/cncr.11897.PubMed

Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck. 2003;25(5):349–56. doi:10.1002/hed.10217.PubMed

Stava C, Beck M, Schultz PN, Vassilopoulou-Sellin R. Hearing loss among cancer survivors. Oncol Rep. 2005;13(6):1193–9.PubMed

Stava C, Beck M, Vassilopoulou-Sellin R. Cataracts among cancer survivors. Am J Clin Oncol. 2005;28(6):603–8. doi:10.1097/01.coc.0000175291.51232.48.PubMed

Stava C, Beck M, Weiss LT, Lopez A, Vassilopoulou-Sellin R. Health profiles of 996 melanoma survivors: the M. D. Anderson experience. BMC Cancer. 2006;6:95. doi:10.1186/1471-2407-6-95.PubMed

10.

Stava C, Weiss LT, Vassilopoulou-Sellin R. Health profiles of 814 very long-term breast cancer survivors. Clin Breast Cancer. 2006;7(3):228–36. doi:10.3816/CBC.2006.n.034.PubMed

11.

Stava CJ, Lopez A, Vassilopoulou–Sellin R. Health profiles of younger and older breast cancer survivors. Cancer. 2006;107(8):1752–9. doi:10.1002/cncr.22200.PubMed

12.

Stava C, Beck M, Feng L, Lopez A, Busaidy N, Vassilopoulou-Sellin R. Diabetes mellitus among cancer survivors. Journal of Cancer Survivorship. 2007;1:102–15.

13.

Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570–93.PubMed

14.

Conde FA, Aronson WJ. Risk factors for male osteoporosis. Urol Oncol. 2003;21(5):380–3. doi:10.1016/S1078-1439(03) 00109-1.PubMed

15.

National Osteoporosis Foundation.Osteoporosis: Fast Facts. 2007; Available from: http://www.nof.org/osteoporosis/diseasefacts.htm.

16.

Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health-Sys Pharm. 2006;63(5):419–30. doi:10.2146/ajhp050045.p1.

17.

World Health Organization.Prevention and Management of Osteoporosis: Report of a WHO Scientific Group (Technical Report Series 921). In A WHO Scientific Group on Prevention and Management of Osteoporosis. 2000. Geneva.

18.

Yeung SC, Gagel RF. Endocrine complications. In: Holland JF, Bast Jr RC, Kufe DW, Pollock RE, Weischelbaum RR, editors. Cancer medicine. Hamilton, Ontario: BC Decker; 2000. p. 2389–98.

19.

Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev. 1998;19(2):144–72. doi:10.1210/er.19.2.144.PubMed

20.

Aksnes LH, Bruland OS. Some musculo-skeletal sequelae in cancer survivors. Acta Oncol (Stockholm, Sweden). 2007;46(4):490–6.

21.

Ottery F. Issues in nutrition, weight and cancer. US Oncol Rev, 2005, 2004.

22.

Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878–82. doi:10.1016/S0140-6736(98)09075-8.PubMed

23.

Hu MI, Gagel RF, Jimenez C. Bone loss in patients with breast or prostate cancer. Cur Osteoporos Rep. 2007;5(4):170–8.

24.

Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplantation. 2000;6(2A):165–74. doi:10.1016/S1083-8791(00)70039-5.

25.

Albright F, Smith P, Richardson AM. Postmenopausal Osteoporosis. JAMA. 1941;116:2465–74.

26.

Miyaura C. Mechanism of bone resorption induced by estrogen deficiency. J Bone and Miner Met. 1994;12(Suppl 2):S3–7. doi:10.1007/BF02383388.

27.

Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157(2):439–44. doi:10.1016/S0022-5347(01)65165-6.PubMed

28.

Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–29.PubMed

29.

Meistrich ML, Vassilopoulou-Sellin R, Lipschultz L. Gonadal dysfunction: effects of cytotoxic agents on adult men. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. Philadelphia, PA: Williams & Wilkin; 1997. p. 2758–73.

30.

Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996;14(11):2923–32.PubMed

31.

Collet-Solberg PF, Sernyak H, Satin-Smith M, Katz LL, Sutton L, Molloy P, et al. Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma. Clin Endocrinol (Oxf). 1997;47(1):79–85. doi:10.1046/j.1365-2265.1997.2211032.x.

32.

Brydoy M, Fossa SD, Dahl O, Bjoro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol (Stockholm, Sweden). 2007;46(4):480–9. doi:10.1080/02841860601166958.

33.

Livesey EA, Brook CG. Gonadal dysfunction after treatment of intracranial tumours. Arch Dis Child. 1988;63(5):495–500. doi:10.1136/adc.63.5.495.PubMed

34.

Daniell HW, Clark JC, Pereira SE, Niazi ZA, Ferguson DW, Dunn SR, et al. Hypogonadism following prostate-bed radiation therapy for prostate carcinoma. Cancer. 2001;91(10):1889–95. doi:10.1002/1097-0142(20010515)91:10<1889::AID-CNCR1211>3.0.CO;2-U.PubMed

35.

Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am. 1998;27(4):927–43. doi:10.1016/S0889-8529(05)70048-7.PubMed

36.

Grigsby PW, Perez CA. The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J Urol. 1986;135(4):726–7.PubMed

37.

Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab. 1993;76(2):288–90. doi:10.1210/jc.76.2.288.PubMed

38.

Garrett TJ, Vahdat LT, Kinne DW. Systemic adjuvant therapy of breast cancer. J Surg Oncol;. 1997;64(2):167–72. doi:10.1002/(SICI) 1096-9098(199702)64:2<167::AID-JSO16>3.0.CO;2-3.PubMed

39.

Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999;54(4):607–11. doi:10.1016/S0090-4295(99)00301-5.PubMed

40.

Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002;56(6):779–86. doi:10.1046/j.1365-2265.2002.01551.x.

41.

Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87(8):3656–61. doi:10.1210/jc.87.8.3656.PubMed

42.

Manni A, Santen R, Harvey H, Lipton A, Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev. 1986;7(1):89–94. doi:10.1210/edrv-7-1-89.PubMed

43.

Allain TJ. Prostate cancer, osteoporosis and fracture risk. Gerontology. 2006;52(2):107–10. doi:10.1159/000090956.PubMed

44.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100(5):892–9. doi:10.1002/cncr.20056.PubMed

45.

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64. doi:10.1056/NEJMoa041943.PubMed

46.

Brown JE, Ellis SP, Silcocks P, Blumsohn A, Gutcher SA, Radstone C, et al. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res. 2006;12(21):6480–6. doi:10.1158/1078-0432.CCR-06-1382.PubMed

47.

Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57(1):127–32. doi:10.1016/S0090-4295(00)00895-5.PubMed

48.

Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175(1):136–9. doi:10.1016/S0022-5347(05)00033-9. discussion 139.PubMed

49.

Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161(4):1219–22. doi:10.1016/S0022-5347(01)61639-2.PubMed

50.

Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR. Maintaining bone health in patients with prostate cancer. Med J Aust. 2006;184(4):176–9.PubMed

51.

Makita K, Ishitani K, Ohta H, Horiguchi F, Nozawa S. Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate. J Bone Miner Metab. 2005;23(5):389–94. doi:10.1007/s00774-005-0618-3.PubMed

52.

McLeod N, Huynh CC, Rashid P. Osteoporosis from androgen deprivation therapy in prostate cancer treatment. Aust Fam Physician. 2006;35(4):243–5.PubMed

53.

Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003;30(6):763–75. doi:10.1053/j.seminoncol.2003.08.028.PubMed

54.

Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer. 2006;7(2):127–32. doi:10.3816/CBC.2006.n.021.PubMed

55.

Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006;11(10):1121–31. doi:10.1634/theoncologist.11-10-1121.PubMed

56.

McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer. 2007;43(17):2523–31. doi:10.1016/j.ejca.2007.08.029.PubMed

57.

Fontanges E, Fontana A, Delmas P. Osteoporosis and breast cancer. Joint Bone Spine. 2004;71(2):102–10. doi:10.1016/j.jbspin.2003.02.001.PubMed

58.

Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326(13):852–6.PubMed

59.

Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14(1):78–84.PubMed

60.

Shah SK, Gecys GT. Prednisone-induced osteoporosis: an overlooked and undertreated adverse effect. J Am Osteopath Assoc. 2006;106(11):653–7.PubMed

61.

Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54(1):49–52. doi:10.1136/ard.54.1.49.PubMed

62.

Adachi JD, Papaioannou A. Corticosteroid-Induced osteoporosis: detection and management. Drug Saf. 2001;24(8):607–24. doi:10.2165/00002018-200124080-00005.PubMed

63.

Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab. 1998;83(3):801–6. doi:10.1210/jc.83.3.801.PubMed

64.

Ragab AH, Frech RS, Vietti TJ. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer. 1970;25(3):580–5. doi:10.1002/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M.PubMed

65.

Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol. 1984;11(1):13–6. doi:10.1007/BF00361126.PubMed

66.

Athanassiadou F, Tragiannidis A, Rousso I, Katsos G, Sidi V, Papageorgiou T, et al. Bone mineral density in survivors of childhood acute lymphoblastic leukemia. Turk J Pediatr. 2006;48(2):101–4.PubMed

67.

Crofton PM, Ahmed SF, Wade JC, Stephen R, Elmlinger MW, Ranke MB, et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab. 1998;83(9):3121–9. doi:10.1210/jc.83.9.3121.PubMed

68.

Wermers RA, Hurley DL, Kearns AE. Osteoporosis associated with megestrol acetate. Mayo Clin Proc. 2004;79(12):1557–61. doi:10.4065/79.12.1557.PubMed

69.

Van Leeuwen BL, Verkerke GJ, Hartel RM, Sluiter WJ, Kamps WA, Jansen HW, et al. Chemotherapy decreases epiphyseal strength and increases bone fracture risk. Clin Orthop Relat Res. 2003;413:243–54. doi:10.1097/01.blo.0000073348.50837.f2.PubMed

70.

Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, et al. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979;63(9–10):1527–31.

71.

Warner JT, Evans WD, Webb DK, Bell W, Gregory JW. Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res. 1999;45(4 Pt 1):544–51. doi:10.1203/00006450-199904010-00014.PubMed

72.

Wang TM, Shih C. Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. Acta Anat. 1986;127(2):93–9. doi:10.1159/000146262.PubMed

73.

Mwale F, Ciobanu I, Demers CN, Antoniou J, Heon S, Servant N, et al. Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats. Calcif Tissue Int. 2005;77(3):175–9. doi:10.1007/s00223-004-0231-9.PubMed

74.

van Leeuwen BL, Hartel R, Jansen HW, Verkerke GJ, Veth RP, Kamps WA, et al. Chemotherapy affects the pattern of failure after shear loading of the proximal tibial growth plate. Arch Orthop Trauma Surg. 2004;124(8):503–6. doi:10.1007/s00402-004-0732-z.PubMed

75.

Beresford JN, Taylor GT, Triffitt JT. Interferons and bone. A comparison of the effects of interferon-alpha and interferon-gamma in cultures of human bone-derived cells and an osteosarcoma cell line. Eur J Biochem. 1990;193(2):589–97. doi:10.1111/j.1432-1033.1990.tb19377.x.PubMed

76.

Gur A, Dikici B, Nas K, Bosnak M, Haspolat K, Sarac AJ. Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? BMC Gastroenterol. 2005;5:30. doi:10.1186/1471-230X-5-30.PubMed

77.

Goodman GR, Dissanayake IR, Gorodetsky E, Zhou H, Ma YF, Jee WS, et al. Interferon-alpha, unlike interferon-gamma, does not cause bone loss in the rat. Bone. 1999;25(4):459–63. doi:10.1016/S8756-3282(99)00182-9.PubMed

78.

Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol. 2000;33(5):812–7. doi:10.1016/S0168-8278(00)80314-1.PubMed

79.

Perez Castrillon JL, Cano-del Pozo M, Sanz-Izquierdo S, Velayos-Jimenez J, Dib-Wobakin W. Bone mineral density in patients with multiple sclerosis: the effects of interferon. Rev Neurol. 2003;36(10):901–3.PubMed

80.

Lehmann T, Beyeler C, Lammle B, Hunziker T, Vock P, Olah AJ, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol. 1996;35(9):898–900. doi:10.1093/rheumatology/35.9.898.PubMed

81.

Waheed A, Kettl PA. Low bone density with the use of valproate. Gen Hosp Psychiatry. 2005;27(5):376–8. doi:10.1016/j.genhosppsych.2005.03.008.PubMed

82.

Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57(3):445–9.PubMed

83.

Ecevit C, Aydogan A, Kavakli T, Altinoz S. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol. 2004;31(4):279–82. doi:10.1016/j.pediatrneurol.2004.03.021.PubMed

84.

Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127(2):256–62. doi:10.1016/S0022-3476(95) 70304-7.PubMed

85.

Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999;55(5):2021–9. doi:10.1046/j.1523-1755.1999.00445.x.PubMed

86.

Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant. 2001;7(5):257–64. doi:10.1053/bbmt.2001.v7.pm11400947.PubMed

87.

Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res. 1999;14(3):342–50. doi:10.1359/jbmr.1999.14.3.342.PubMed

88.

Sambrook PN. Cyclosporine and bone mass. Clin Exp Rheumatol. 2000;18(Suppl 21):S93–6.

89.

Kerschan-Schindl K, Mitterbauer M, Fureder W, Kudlacek S, Grampp S, Bieglmayer C, et al. Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplant. 2004;34(6):491–6. doi:10.1038/sj.bmt.1704618.PubMed

90.

Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf. 2007;30(1):27–46. doi:10.2165/00002018-200730010-00004.PubMed

91.

Jackson HA, Sheehan AH. Effect of vitamin A on fracture risk. Ann Pharmacother. 2005;39(12):2086–90. doi:10.1345/aph.1G028.PubMed

92.

Melhus H, Michaelsson K, Kindmark A, Bergstrom R, Holmberg L, Mallmin H, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med. 1998;129(10):770–8.PubMed

93.

Saino H, Matsuyama T, Takada J, Kaku T, Ishii S. Long-term treatment of indomethacin reduces vertebral bone mass and strength in ovariectomized rats. J Bone Miner Res. 1997;12(11):1844–50. doi:10.1359/jbmr.1997.12.11.1844.PubMed

94.

Goodman SB, Jiranek W, Petrow E, Yasko AW. The effects of medications on bone. J Am Acad Orthop Surg. 2007;15(8):450–60.PubMed

95.

van Staa TP, Leufkens HG, Cooper C. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone. 2000;27(4):563–8. doi:10.1016/S8756-3282(00)00361-6.PubMed

96.

Kumaki SK. H. Effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on osteoporosis. J Jpn Assoc Rural Med. 2001;50(2):96–101.

97.

Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res. 2003;18(10):1795–802. doi:10.1359/jbmr.2003.18.10.1795.PubMed

98.

Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1996;11(1):29–35.PubMedCrossRef

99.

Taube T, Kylmala T, Lamberg-Allardt C, Tammela TL, Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer. 1994;30A(6):751–8. doi:10.1016/0959-8049(94)90287-9.PubMed

100.

Citrin DL, Wallemark CB, Nadler R, Geiger C, Tuttle K, Kaplan EH, et al. Estramustine affects bone mineral metabolism in metastatic prostate cancer. Cancer. 1986;58(10):2208–13. doi:10.1002/1097-0142(19861115)58:10<2208::AID-CNCR2820581008>3.0.CO;2-A.PubMed

101.

Yamada Y, Takahashi S, Fujimura T, Nishimatsu H, Ishikawa A, Kume H, et al. The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. Osteoporos Int. 2008;19(3):321–7. doi:10.1007/s00198-007-0472-3.PubMed

102.

Church DN, Hassan AB, Harper SJ, Wakeley CJ, Price CG. Osteomalacia as a late metabolic complication of Ifosfamide chemotherapy in young adults: illustrative cases and review of the literature. Sarcoma. 2007. 91586.

103.

Duck L, Devogelaer JP, Persu A, Berliere M, Caussin E, Baurain JF, et al. Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient. Gynecol Oncol. 2005;98(2):329–31. doi:10.1016/j.ygyno.2005.05.014.PubMed

104.

Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24(1):19–38. doi:10.2165/00002018-200124010-00003.PubMed

105.

Bluemke DA, Fishman EK, Scott WW Jr. Skeletal complications of radiation therapy. Radiographics. 1994;14(1):111–21.PubMed

106.

Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial review. Eur Radiol. 2006;16(3):619–33. doi:10.1007/s00330-005-0010-7.PubMed

107.

Hopewell JW. Radiation-therapy effects on bone density. Med Pediatr Oncol. 2003;41(3):208–11. doi:10.1002/mpo.10338.PubMed

108.

Vassilopoulou-Sellin R, Brosnan P, Delpassand A, Zietz H, Klein MJ, Jaffe N. Osteopenia in young adult survivors of childhood cancer. Med Pediatr Oncol. 1999;32(4):272–8. doi:10.1002/(SICI)1096-911X(199904) 32:4<272::AID-MPO6>3.0.CO;2-G.PubMed

109.

Adler RA. Cancer treatment-induced bone loss. Curr Opin Endocrinol Diabetes Obes. 2007;14(6):442–5.PubMed

110.

Mitchell MJ, Logan PM. Radiation-induced changes in bone. Radiographics. 1998;18(5):1125–36. quiz 1242–3.PubMed

111.

Hirbe A, Morgan EA, Uluckan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clin Cancer Res. 2006;12(20 Pt 2):6309s–14. doi:10.1158/1078-0432.CCR-06-0652.PubMed

112.

Iyer RB, Libshitz HI. Late sequelae after radiation therapy for breast cancer: imaging findings. AJR Am J Roentgenol. 1997;168(5):1335–8.PubMed

113.

Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys. 1992;23(5):915–23.PubMed

114.

Overgaard M. Spontaneous radiation-induced rib fractures in breast cancer patients treated with postmastectomy irradiation. A clinical radiobiological analysis of the influence of fraction size and dose-response relationships on late bone damage. Acta Oncol (Stockholm, Sweden). 1988;27(2):117–22. doi:10.3109/02841868809090331.

115.

Bonfiglio M. The pathology of fracture of the femoral neck following irradiation. Am J Roentgenol Radium Ther Nucl Med. 1953;70(3):449–59.PubMed

116.

Libshitz HI, Edeiken BS. Radiotherapy changes of the pediatric hip. AJR Am J Roentgenol. 1981;137(3):585–8.PubMed

117.

Iyer RB, Jhingran A, Sawaf H, Libshitz HI. Imaging findings after radiotherapy to the pelvis. AJR Am J Roentgenol. 2001;177(5):1083–9.PubMed

118.

van Leeuwen BL, Kamps WA, Jansen HW, Hoekstra HJ. The effect of chemotherapy on the growing skeleton. Cancer Treat Rev. 2000;26(5):363–76. doi:10.1053/ctrv.2000.0180.PubMed

119.

Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, et al. Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med. 2005;165(5):552–8. doi:10.1001/archinte.165.5.552.PubMed

120.

Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005;135(11):2739S–48.PubMed

121.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. doi:10.1056/NEJMra070553.PubMed

122.

Reid IR. Glucocorticoid-induced osteoporosis. Best Pract Res Clin Endocrinol Metab. 2000;14(2):279–98. doi:10.1053/beem.2000.0074.

123.

Ria R, Scarponi AM, Falzetti F, Ballanti S, Di Ianni M, Sportoletti P, et al. Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. Leuk Lymphoma. 2007;48(5):923–30. doi:10.1080/10428190701268775.PubMed

124.

Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transpl. 2003;17(3):268–74. doi:10.1034/j.1399-0012.2003.00047.x.

125.

Kulak CA, Borba VZ, Kulak Junior J, Shane E. Transplantation osteoporosis. Arq Bras Endocrinol Metabol. 2006;50(4):783–92. doi:10.1590/S0004-27302006000400023.PubMed

126.

Rosen IB, Strawbridge HG, Bain J. A case of hyperparathyroidism associated with radiation to the head and neck area. Cancer. 1975;36(3):1111–4. doi:10.1002/1097-0142(197509)36:3<1111::AID-CNCR2820360341>3.0.CO;2-9.PubMed

127.

Christmas TJ, Chapple CR, Noble JG, Milroy EJ, Cowie AG. Hyperparathyroidism after neck irradiation. Br J Surg. 1988;75(9):873–4. doi:10.1002/bjs.1800750914.PubMed

128.

Ippolito G, Palazzo FF, Sebag F, Henry JF. Long-term follow-up after parathyroidectomy for radiation-induced hyperparathyroidism. Surgery. 2007;142(6):819–22. discussion 822 e1.PubMed

129.

Kalaghchi B, Brietzke SA, Drake AJ 3rd, Shakir KM. Effects of prior neck radiation therapy on clinical features of primary hyperparathyroidism and associated thyroid tumors. Endocr Pract. 2003;9(5):353–62.PubMed

130.

Alpert PT, Shaikh U. The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems. Biol Res Nurs. 2007;9(2):117–29. doi:10.1177/1099800407308057.PubMed

131.

Bandeira F, Griz L, Dreyer P, Eufrazino C, Bandeira C, Freese E. Vitamin D deficiency: A global perspective. Arq Bras Endocrinol Metabol. 2006;50(4):640–6.PubMed

132.

Baker MR, McDonnell H, Peacock M, Nordin BE. Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck. Br Med J. 1979;1(6163):589.PubMed

133.

Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90(6):3215–24. doi:10.1210/jc.2004-2364.PubMed

134.

Kinoshita Y, Masuoka K, Miyakoshi S, Taniguchi S, Takeuchi Y. Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. Bone. 2008;42(1):226–8. doi:10.1016/j.bone.2007.09.042.PubMed

135.

Cohran VC, Griffiths M, Heubi JE. Bone mineral density in children exposed to chronic glucocorticoid therapy. Clin Pediatr. 2008;47(5):469–75. doi:10.1177/0009922807311732.

136.

Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354(19):2006–13. doi:10.1056/NEJMoa051140.PubMed

137.

Grey A, O’Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med. 2006;355(23):2494–5. doi:10.1056/NEJMc062388.PubMed

138.

Osorio S, Noblejas AG, Duran A, Steegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol. 2007;82(5):394–5. doi:10.1002/ajh.20778.PubMed

139.

Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12(1):107–13. doi:10.1634/theoncologist.12-1-107.PubMed

140.

Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12(24):7271–8. doi:10.1158/1078-0432.CCR-06-1249.PubMed

141.

Heiskanen JT, Kroger H, Paakkonen M, Parviainen MT, Lamberg-Allardt C, Alhava E. Bone mineral metabolism after total gastrectomy. Bone. 2001;28(1):123–7. doi:10.1016/S8756-3282(00)00404-X.PubMed

142.

Zittel TT, Zeeb B, Maier GW, Kaiser GW, Zwirner M, Liebich H, et al. High prevalence of bone disorders after gastrectomy. Am J Surg. 1997;174(4):431–8. doi:10.1016/S0002-9610(97) 00123-2.PubMed

143.

von Tirpitz C, Reinshagen M. Management of osteoporosis in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol. 2003;15(8):869–76. doi:10.1097/00042737-200308000-00006.

144.

Imawari M, Kozawa K, Akanuma Y, Koizumi S, Itakura H, Kosaka K. Serum 25-hydroxyvitamin D and vitamin D-binding protein levels and mineral metabolism after partial and total gastrectomy. Gastroenterology. 1980;79(2):255–8.PubMed

145.

Bisballe S, Eriksen EF, Melsen F, Mosekilde L, Sorensen OH, Hessov I. Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. Gut. 1991;32(11):1303–7. doi:10.1136/gut.32.11.1303.PubMed

146.

Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest. 2005;28(1):12–7.PubMed

147.

Lim JS, Kim SB, Bang HY, Cheon GJ, Lee JI. High prevalence of osteoporosis in patients with gastric adenocarcinoma following gastrectomy. World J Gastroenterol. 2007;13(48):6492–7. doi:10.3748/wjg.13.6492.PubMed

148.

Vartej P, Poiana C, Vartej I. Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol. 2001;15(1):43–7. doi:10.1080/713602650.PubMed

149.

Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2008.

150.

Constine LS, Rubin P, Woolf PD, Doane K, Lush CM. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol. 1987;5(11):1841–51.PubMed

151.

Zadrozna-Sliwka B, Bolanowski M, Kaluzny M, Syrycka J. Bone mineral density and bone turnover in hyperprolactinaemia of various origins. Endokrynol Pol. 2007;58(2):116–22.PubMed

152.

Sklar CA, Constine LS. Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1113–21. doi:10.1016/0360-3016(94)00427-M.PubMed

153.

Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary. 2005;8(3–4):203–11. doi:10.1007/s11102-006-6042-4.PubMed

Title: Skeletal sequelae of cancer and cancer treatment
Authors: Charles J. Stava
Camilo Jimenez
Mimi I. Hu
Rena Vassilopoulou-Sellin
Publication date: 01-06-2009
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 2/2009
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-009-0083-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Discussion/Conclusions

Implications for cancer survivors

Please log in to get access to this content

Other articles of this Issue 2/2009

Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer

Emotional distress impacts fear of the future among breast cancer survivors not the reverse

Cancer survivors need evidence on how to optimize physical function

The views of bowel cancer survivors and health care professionals regarding survivorship care plans and post treatment follow up

Is somatic comorbidity associated with more somatic symptoms, mental distress, or unhealthy lifestyle in elderly cancer survivors?

Problem-solving style and adaptation in breast cancer survivors: a prospective analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer